About Compass Therapeutics
Compass Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2013. Therapeutic antibodies for cancer treatment are discovered and developed. Compass Therapeutics has raised $238.46 million across 5 funding rounds from investors including BioMed Realty, TD Securities and Orbimed. The company has 35 employees. Compass Therapeutics has completed 1 acquisition, including TRIGR Therapeutics. Compass Therapeutics offers products and services including COMPANION-002, COMPANION-003, CTX-471, and CTX-8371. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Compass Therapeutics was founded in 2013 and is headquartered in Cambridge, United States. Operations center on the discovery and development of therapeutic antibodies targeting cancer. Focus is placed on combinations of human monoclonal antibodies, multiclonal mixtures, and engineered protein constructs to address the tumor-immune synapse. The company operates within the biotechnology sector, emphasizing oncology applications.
- Headquarters Cambridge, United States
- Employees 35
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website compasstherapeutics.com
- Social LinkedIn X
- Legal Name Compass Therapeutics, Inc.
- Net Profit-$66.49 M (USD)-34.66as on Dec 31, 2025
- EBITDA-$71.37 M (USD)-30.06as on Dec 31, 2025
- Total Equity Funding$238.46M (USD)
in 5 rounds
- Latest Funding Round$60.48M (USD), Series A
Jun 2020
- InvestorsBioMed Realty
& 11 more
- Employee Count35
- Investments & Acquisitions
Products & Services of Compass Therapeutics
Compass Therapeutics offers a comprehensive portfolio of products and services, including COMPANION-002, COMPANION-003, CTX-471, and CTX-8371.
Trial for first-line treatment of biliary tract cancer using antibodies.
Trial advancing cancer therapies through immune response optimization.
Antibody therapy combined with KEYTRUDA for cancer treatment.
Product candidate targeting tumor microenvironment in oncology.
Funding Insights of Compass Therapeutics
Compass Therapeutics has successfully raised a total of $238.46M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $60.48 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $238.46M
- Total Rounds 5
- Last Round Series A — $60.48M
- First Round $575,000
(May 2015)
- Investors Count 12
All 5 funding rounds of Compass Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $60.48M | Series A | – | Consonance Capital | |
| Jul 2018 | $132M | Series A | – | Orbimed | |
| Sep 2016 | $45.98M | Series A | – | – | |
| Jun 2015 | Series A | – | – | ||
| May 2015 | $575,000 | Debt – Convertible | – | – | – |
12 investors in total: 11 institutional and 1 angel.
Investors in Compass Therapeutics
Compass Therapeutics has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include BioMed Realty, TD Securities and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Venture capital firm investing in seed & series A startups | borealis.vc | Hanover, United States | ||
Early-stage tech and life sciences focused VC firm investing primarily in the US | biomaticscapital.com | Seattle, United States | ||
| ulyssesholdings.com | ||||
| consonancecapital.com | ||||
Thiel Capital is involved in investment and financial activities. | thielcapital.com | |||
Early stage investments focused VC firm | acks.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States |
Investor details for Compass Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Compass Therapeutics
27 people are tracked at Compass Therapeutics (12 in leadership, 12 in board & advisors, 3 in team); the tracked headcount is 35.
| Name | Role | Group |
|---|---|---|
Barry Shin | Chief Financial Officer | Leadership |
Vered Bisker-Leib | President & COO | Leadership |
Neil Lerner | VP, Finance | Leadership |
Thomas J. Schuetz | Co-Founder & CEO | Leadership |
Karin Herrera | VP & Head of Clinical Operations | Leadership |
Ian Chia | VP of Business Development & Strategy | Leadership |
Jonathan Anderman | VP, Head of Legal & Corporate Secretary | Leadership |
Neal Schilling | Director - Manufacturing | Leadership |
James Kranz | VP & Head of Chemistry Manufacturing & Controls | Leadership |
Anna Gifford | Chief Of Staff | Leadership |
Ian Chia, Ph.D. | Vice President of Business Development & Strategy | Leadership |
Diana Albu | Associate Director | Leadership |
Patricia Lorusso | Advisor | Board & advisors |
Daniel D. Von Hoff | Advisor | Board & advisors |
James Boylan | Director | Board & advisors |
Edward Chu | Advisor | Board & advisors |
F. Stephen Hodi | Scientific Advisor | Board & advisors |
Carl L. Gordon | Board Member | Board & advisors |
Mary Ann Gray | Board Member | Board & advisors |
Richard S. Lindahl | Director | Board & advisors |
7 more people are available in the full profile.
Complete people profiles for Compass Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Compass Therapeutics
Compass Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CMPX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Apr 2021
- Listed onNASDAQ: CMPX
- Listed entityCompass Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS20454B1044
- Share price$0.86 (-8.59% on the day) · 2026-10-13
- Market capitalisation$154.3M
- EPS (diluted, trailing year)$-0.40
- Volume (last session)3,798,069
Financials of Compass Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$66.5M | -$71.4M | |
| 2024 | $850,000 | -$49.4M | -$54.9M |
| 2023 | -$42.5M | -$48.5M | |
| 2022 | -$39.2M | -$39.8M | |
| 2021 | -$82.2M | -$29.6M |
Detailed financial statements for Compass Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Compass Therapeutics
Compass Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include TRIGR Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapeutics for cancer are developed by the company. | trigrrx.com | Irvine, United States | 2018 | May 2021 | •••• |
Complete acquisition details for Compass Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Compass Therapeutics
5 dated milestones of Compass Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Compass Therapeutics is founded.
- Funding First funding round of $575K.
- Funding Latest funding round, Series A, of $60.5M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires TRIGR Therapeutics.
Competitors of Compass Therapeutics
Compass Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Compass Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Compass Therapeutics
The website of Compass Therapeutics (compasstherapeutics.com) receives about 8.7K visits a month and ranks #3,518,435 among all websites worldwide, #4,556 in Biotechnology and Pharmaceuticals.
- Monthly visits8.7K
▲ 64.1% vs previous month
- Unique visitors2.3K
per month
- Global rank#3,518,435
among all websites
- Category rank#4,556
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.8
- Average visit11 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Compass Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cuebiopharma.com | 100% | 4.9K | #7,063,180 | View details | |
| sherlock.bio | 97% | 2.8K | #4,929,420 | View details | |
| ornatx.com | 95% | 4.4K | #3,250,511 | View details | |
| lyndra.com | 95% | #9,629,878 | View details | ||
| dynotx.com | 93% | 14.4K | #2,089,404 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Compass Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Compass Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Compass Therapeutics
Complete news archive for Compass Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Compass Therapeutics
Compass Therapeutics was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Compass Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Compass Therapeutics is a funded company, having raised a total of $238.46M across 5 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $575K, raised on May 2015.
Compass Therapeutics has 35 employees.
Compass Therapeutics was founded in 2013 and is headquartered in Cambridge, United States. Operations center on the discovery and development of therapeutic antibodies targeting cancer. Focus is placed on combinations of human monoclonal antibodies, multiclonal mixtures, and engineered protein constructs to address the tumor-immune synapse. The company operates within the biotechnology sector, emphasizing oncology applications.
Compass Therapeutics's top competitors include C4 Therapeutics, Erasca and MiRagen.
Compass Therapeutics offers COMPANION-002, COMPANION-003, CTX-471, and CTX-8371.
Yes, Compass Therapeutics is publicly traded on NASDAQ under the ticker symbol CMPX.
Compass Therapeutics has made 1 acquisition, including TRIGR Therapeutics.
Compass Therapeutics has 12 investors. Key investors include BioMed Realty, TD Securities, Orbimed, F-Prime Capital, and Borealis Ventures.